Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 759-767

  Cescon, David W ^a,b   Ganz, Patricia A ^c,d   Beddows, Samantha ^a   Ennis, Marguerite ^e   Mills, Barbara K ^d   Goodwin, Pamela J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE

Author keywords

Adjuvant therapy; Breast cancer; Outcomes; Randomized controlled trials; Vitamin D

Indexed keywords

CALCIFEDIOL; PLACEBO;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WAIST CIRCUMFERENCE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIETARY SUPPLEMENTS; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SELECTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS, NONPARAMETRIC; VITAMIN D; VITAMINS;

EID: 84868198096     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2120-7     Document Type: Article

References (26)

1. Goodwin PJ (2009) Vitamin D in cancer patients: above all, do no harm. J Clin Oncol 27:2117-2119. doi:10.1200/JCO.2008. 20.8629
2. Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press, Washington DC
3. Chlebowski RT (2011) Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Res 13:217. doi:10.1186/bcr2846
4. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586-1591
5. Anderson LN, Cotterchio M, Vieth R, Knight JA (2010) Vitamin D and calcium intakes and breast cancer risk in pre-and postmenopausal women. Am J Clin Nutr 91:1699-1707. doi:10.3945/ajcn. 2009.28869
6. http://www.cancer.ca/Canada-wide/Prevention/Vitamin%20D/UV %20%20Vitamin%20D%20and%20Health%20Conference.aspx. Accessed 12 Sep. 2011
7. http://www.dermatology.ca/media/position-statement/vitamin-d.html. Accessed 2 Oct. 2011
8. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N (2009) Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27:3757-3763. doi:10.1200/JCO.2008. 20.0725
9. Kim HJ, Lee YM, Ko BS et al (2011) Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer. Ann Surg Oncol 18:1830-1836. doi:10.1245/s10434-010-1465-6
10. Vrieling A, Hein R, Abbas S et al (2011) Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 13:R74. doi:10.1186/bcr2920
11. Jacobs ET, Thomson CA, Flatt SW et al (2011) Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. Am J Clin Nutr 93:108-117. doi:10.3945/ajcn. 2010.30009
12. Ahn J, Peters U, Albanes D et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100:796-804. doi:10.1093/jnci/djn152
13. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA et al (2010) Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 172:81-93. doi:10.1093/aje/ kwq120
14. Stambolsky P, Tabach Y, Fontemaggi G et al (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17:273-285. doi:10.1016/j.ccr.2009.11.025
15. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629. doi:10.1002/humu.20495
16. Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39-51. doi:10.1001/jama.2008.864
17. Knight JA, Lesosky M, Barnett H, Raboud JM, Vieth R (2007) Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16:422-429. doi:10.1158/1055-9965. EPI-06-0865
18. Sahota H, Barnett H, Lesosky M et al (2008) Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev 17:232-238. doi:10.1158/1055-9965. EPI-07-0632
19. Block G, Hartman AM, Dresser CM et al (1986) A data-based approach to diet questionnaire design and testing. Am J Epidemiol 124:453-469
20. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266-281. doi:10.1056/NEJMra070553
21. Statistics Canada (2010) Canadian Health Measures Survey: Cycle 1 2007 to 2009. 82-623-X, no. 2
22. Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. doi:10.1093/annonc/ mdr017
23. Chlebowski RT, Johnson KC, Kooperberg C et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581-1591. doi:10.1093/jnci/djn360
24. Peppone LJ, Huston AJ, Reid ME et al (2011) The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat 127:171-177. doi:10.1007/s10549-011-1415-4
25. Yao S, Sucheston LE, Millen AE et al (2011) Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One 6:e17251. doi:10.1371/journal.pone.0017251
26. Khan QJ, Reddy PS, Kimler BF et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119:111-118. doi:10.1007/s10549-009-0495-x